KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Receivables: 2011-2024

Historic Receivables for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $146.1 million.

  • Supernus Pharmaceuticals' Receivables rose 22.11% to $177.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $615.5 million, marking a year-over-year increase of 4.36%. This contributed to the annual value of $146.1 million for FY2024, which is 1.33% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Receivables stood at $146.1 million for FY2024, which was up 1.33% from $144.2 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Receivables peaked at $165.5 million during FY2022, and registered a low of $140.9 million during FY2020.
  • Moreover, its 3-year median value for Receivables was $146.1 million (2024), whereas its average is $151.9 million.
  • In the last 5 years, Supernus Pharmaceuticals' Receivables soared by 61.31% in 2020 and then fell by 12.90% in 2023.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Receivables stood at $140.9 million in 2020, then increased by 5.72% to $148.9 million in 2021, then rose by 11.12% to $165.5 million in 2022, then decreased by 12.90% to $144.2 million in 2023, then rose by 1.33% to $146.1 million in 2024.